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Abstract
Regardless of its etiology, chronic kidney disease (CKD) is characterized by proteinuria, 
serum creatinine retention, glomerulosclerosis (GS), and tubulointerstitial damage. 
Notably, the last one has been correlated more closely with the evolution to kidney fail-
ure than the extent of glomerular injury. Tubulointerstitial inflammation comprises the 
activation of tubular epithelial cells, which release inflammatory mediators and chemo-
kines promoting the influx of leukocytes in the renal parenchyma and the activation/pro-
liferation of resident fibroblasts, leading to excessive production of extracellular matrix 
(EM), fibrosis, and renal function loss. Therefore, inflammation exerts a key role in the 
pathogenesis of CKD, although the mechanisms by which this process is activated and 
perpetuated, even when the initial insult is not immune-mediated, such as in the hyper-
tensive nephrosclerosis, in the diabetic nephropathy, and in the crystal-induced renal 
disease, remain unclear. This chapter provides an overview on inflammation and CKD 
development not related to autoimmunity or caused by presence of foreign antigens. 
Cellular and molecular mechanisms involved in different pathways and its potential 
therapeutic targets to detain the progression of inflammation and fibrosis in CKD are 
also presented ahead as a contribution in this book.
Keywords: chronic kidney disease, inflammation, immune system, innate immunity, 
adaptive immunity
1. Introduction
Chronic kidney disease (CKD) is considered a global health problem that motivates life 
science researchers and physicians to investigate the mechanisms beyond its development, 
and to seek for new therapeutic strategies to detain the evolution of renal function loss [1]. 
© 2018 The Author(s). Licensee InTech. This chapt r is distributed under the terms of the Creative Comm s
Attribution L cense (http://creativecommons. /licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Progressive CKD may be initiated by several conditions of different etiological basis; how-
ever, in almost all cases, renal disease progresses with the development of a chronic and 
self-sustained inflammatory reaction, which involves both innate and adaptive arms of 
immune response and leads to kidney fibrosis. Reasons why inflammation parallels CKD 
progression even when the initial renal injury does not involve autoimmune disorders or 
infection episodes remain unclear [2]. In the following sections, we are going to discuss 
some epidemiological data on CKD in the United States (US) and in the World, as well 
as briefly review the pathophysiological mechanisms involved in CKD development and 
progression, with special attention to the participation of inflammatory components in this 
process.
2. Chronic kidney disease and inflammation: definition and numbers
CKD is a general term used to define a group of heterogeneous disorders that structurally 
compromise the kidneys, resulting in reduction or insufficiency of renal function. CKD is one 
of the major degenerative conditions that lead to progressive disability, and is the ninth cause 
of death in the US [3]. Every year, kidney disease kills more people than breast or prostate 
cancer. According to the National Kidney Foundation, CKD assumed epidemic proportions 
in the last decades and meets all the required criteria to be considered as a major public health 
concern [3–8]. The 2016 Annual Data Report of the US Renal Data System (USRDS) showed 
that around 26 millions of American adults have some degree of kidney disease, of which, 
more than 661,000 have end-stage renal disease (ESRD), defined by the requirement of renal 
replacement therapy (RRT) for life-saving [4, 5]. Accordingly, there were 468,000 Americans 
on dialysis and approximately 193,000 individuals living with a transplanted kidney, in the 
last year [5].
This reality is also true for the other countries around the world. The Bulletin of the World 
Health Organization estimated the global number of patients receiving RRT to be higher than 
1.4 million, with incidence of growing by around 8% annually [6]. This high prevalence and 
mortality, allied to the elevated costs of treating this growing epidemic represents a big burden 
on healthcare systems worldwide, especially in low and middle income countries, where long 
term dialysis is financially unaffordable [7–9]. This dramatic scenario motivates the medical 
community to intensify the efforts in preventing kidney injury and to improve the early detec-
tion of this condition. Moreover, scientific investigation to elucidate the pathophysiological 
mechanisms involved in the evolution of chronic nephropathies is of paramount importance 
to the development of more effective therapeutic strategies to slow or even stop the progres-
sion of CKD.
Gradual renal function deterioration is generally caused by an initial kidney injury, which 
acutely or chronically affects both the glomerular filtration rate (GFR) and/or the tubular reab-
sorption/excretion [2, 10]. The decrease of renal blood flow and the blockage of the urinary 
tract are the main causes of acute kidney injury (AKI). Kidneys’ hypoperfusion can be caused 
by hypovolemia, septic shock, bleeding, hypotension, or due to renal ischemia, caused by 
abnormal vasoconstriction, or by the presence of blood clots, arteriosclerosis or other renal 
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blood flow blocking agents. Bladder and/or ureteral obstruction, in turn, can occur due to 
anatomic alterations, prostate hypertrophy, and cancer, or by the presence of kidney/ureteral 
stones. AKI can be additionally caused by some specific health conditions such as the mul-
tiple myeloma or the tubular necrosis, which can result from the administration of nephro-
toxic drugs and compounds. In general, these conditions reduce the GFR, promoting a sharp 
decrease of renal function, that can be transitory; if the renal blood hypoperfusion or the 
obstruction of the urinary tract is rapidly corrected, or permanent, if the regular renal blood 
flow and the urinary output are not restored. There are actually growing evidence that, even 
when an AKI episode is properly solved, and there is a complete reestablishment of renal 
function, the patients should be closely followed for a long period, since this population is 
more prone to manifest CKD in the future [10, 11].
Although acute renal lesions may lead to the development of progressive kidney insuffi-
ciency, the two main causes of CKD are still diabetes and hypertension [3–6]. Such insidious 
diseases are, together, responsible for up to two-thirds of the cases of CKD in the American 
population [3–5]. If poorly or inefficiently controlled, both diabetes and hypertension may 
cause significant damage to human body, especially when it is exposed to these conditions 
for a long period. Many organs and systems can be affected, such as the blood vessels, the 
central nervous system (CNS), the eyes and, finally, the kidneys [2, 10]. The exact patho-
physiological mechanisms through which sustained high serum glucose concentration and 
blood pressure lead to renal injury have not yet been fully elucidated. Proposed theories and 
mechanisms based on experimental studies, clinical trials, and medical observation will be 
discussed further on.
The third more common cause of CKD in the US is a group of autoimmune disorders, gener-
ally designated by Glomerulonephritis (GN) [3–5]. There are a number of different kinds of 
GN, which differ one from the other by the type of local renal infiltrating cells, by the presence 
and subtyping of autoantibodies, by the accumulation of complement system components, 
by the specific antigens that starts the renal local immune response, and also by some dif-
ferential clinical and laboratorial features, including proteinuria, hematuria, and edema [12]. 
Although GN is an important cause of CKD, the molecular and cellular mechanisms involved 
in their onset and progression are beyond the scope of this revision, since GN is considered 
an immune-mediated kidney condition.
In a less extent, inherited diseases like different forms of polycystic kidney disease (PKD) and 
genetic syndromes, such as Von Hippel-Lindau, Alport’s, and Bartter’s can also lead to CKD, 
as well as congenital malformations of the urinary system and repeated urinary tract infec-
tions (UTI) [3–6, 13].
3. Overview of CKD pathophysiology
Regardless of the nature of the initial renal insult, CKD is characterized by proteinuria, 
serum urea and creatinine retention, blood pressure rising, and imbalance in renal per-
fusion, which lead to the development of glomerular hypertension and hypertrophy, 
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mesangial cells proliferation, and extracellular matrix (EM) overproduction, culminating 
in irreversible changes in glomerular and tubular architecture that impairs the function of 
the nephron [2, 9]. Notably, the involvement of the tubulointerstitial compartment has been 
correlated more closely with the evolution to kidney failure than the extent of glomerular 
injury per se [2, 9, 14]. The more filtering units are injured, the more overburdened the 
remaining nephrons become, which in turn end up succumbing due to overload in a vicious 
cycle of positive feedback. This process leads to global glomerulosclerosis (GS), tubular 
atrophy (TA), interstitial fibrosis, peritubular capillary rarefaction, and progressive renal 
function loss [2, 9, 14, 15], as illustrated in Figure 1.
The inordinate activation of the renin-angiotensin-aldosterone system (RAAS) is one of 
the major factors that can stimulate CKD progression [9]. Traditionally, RAAS used to 
be considered only as an endocrine system, whose major function was to maintain the 
blood pressure, even in situations of hypovolemia [16]. In the traditional description of 
RAAS, Renin, a hormone synthesized by the renal juxtaglomerular cells, promotes the 
conversion of angiotensinogen, produced in the liver, into angiotensin I (Ang I). This pep-
tide is further cleaved by angiotensin-converting enzyme (ACE) into its active form, the 
Angiotensin II (Ang II), which, in turn, binds to its specific receptors (AT1) in the adre-
nal cortex, resulting in the release of aldosterone. Once released in the blood stream this 
Figure 1. CKD pathophysiology. Different immune and nonimmune conditions may cause the initial renal insult that is 
been influenced by both modifiable and non-modifiable risk factors. This original damage causes several changes on renal 
function reducing the glomerular filtration rate, impairing the renal tubular hydroelectrolytic balance and damaging the 
glomerular filtration barrier. In a forward positive feedback, these events are able to lead to glomerulosclerosis, renal 
fibrosis and progressive loss of function.
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mineralocorticoid steroid promotes renal and systemic vasoconstriction and tubular 
sodium conservation, leading to the elevation of blood pressure [9, 16]. In spite of its first 
description, RAAS became much more complex in the recent years, after the identification 
of many novel components, such as the enzyme chymase, which exerts the same function 
of ACE, the biologically active peptides angiotensin III, IV, 1–9 and 1–7, and a number of 
different Ang II receptors (AT2, AT4, among others) [16]. Moreover, depending on which 
intracellular downstream system is activated by Ang II, different physiological responses 
can be triggered [16, 17].
Ang II has been related to inflammation followed to chronic nephropathy developed by 
the enhancing of the immune response and favoring renal infiltration by leukocyte [18, 19]. 
Additionally, there are growing in vitro and in vivo evidence that Ang II promotes cell pro-
liferation and fibroblast activation, worsening the accumulation of EM and contributing 
to the development of renal fibrosis [18, 20, 21]. Furthermore, a variety of studies showed 
the presence of both Ang II and the receptor AT1 in the renal parenchyma of animals sub-
mitted to experimental models of CKD, leading to the discovery of a complex intrarenal 
pro-inflammatory RAAS that seems to become overactivated under kidney injury [18–22]. 
Accordingly, suppression of RAAS with both ACE inhibitors (ACEi) and/or AT1 receptor 
blockers (ARB) become a mainstay of treatment of progressive nephropathies and, although 
several innovative therapeutic measures have been recently proposed for the treatment of 
CKD, RAAS blockage, associated to diuretics or not, remains the best available resource in 
this regard [9, 16, 23, 24].
In 1984, Schwartz and collaborators demonstrated for the first time an increase in fibroblast 
and the appearance of macrophages and lymphocytes in the renal parenchyma of rabbits 
submitted to a sterile model of renal ischemia/reperfusion [25]. This was one of the first stud-
ies suggesting that the inflammatory process, including mononuclear cell infiltration and 
fibroblast proliferation was a final pathway common to different forms of renal injury, inde-
pendent of its etiology. We currently know that inflammation exerts a key role in the patho-
genesis of CKD, although the mechanisms by which this process is activated and perpetuated, 
even when the initial insult is not immune-mediated, remain unclear.
There is growing evidence that the activation of both cellular and humoral immunity is 
related to the progression of renal insufficiency and a worse prognosis in nonimmune-
mediated CKD. Renal infiltration by macrophages has been demonstrated in a variety of 
human nonimmune-mediated renal diseases, such as diabetic nephropathy (DN) [26] and 
hypertensive nephrosclerosis (HN) [27]. Moreover, this phenomenon was also observed 
in different experimental models of CKD over the last years. Accordingly, the number of 
inflammatory cells in the renal interstitium closely correlates with the severity of nephropa-
thy and with glomerular and tubulointerstitial lesions in these experimental models [28–30]. 
The increase of dendritic cells (DCs) in the renal parenchyma, in turns, is believed to indi-
cate the spreading of inflammation from glomerular to the tubulointerstitial compartment, 
playing a pivotal role in the progression of both AKI and CKD [31, 32]. Finally, cortical 
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T-lymphocyte infiltration is a common finding in both genetic [33] and pharmacologically 
induced [34] DN in rodents. Moreover, it has also been described in the 5/6 renal ablation 
model (NX) [35] and in the chronic inhibition of nitric oxide synthase model (L-NAME) [29], 
among others [19]. In most of these studies, the amount of T-cells in the renal interstitium 
correlates positively with the progression of albuminuria, creatinine retention, and renal 
structural damage, as shown in Table 1 [36–43]. Corroborating these findings, a number 
of experimental studies showing significant evidence that anti-inflammatory treatment, as 
well as the knockout (KO) of specific pro-inflammatory genes can be effective to detain the 
evolution of nephropathy in different animal models of CKD, have been recently published, 
as shown in Table 2 [44–52].
Although the exact sequence of the inflammatory events in progressive CKD has not been 
completely elucidated yet, we are currently aware that, the activation of tubular epithelial 
cells, inordinate production of cytokines, activation of resident phagocytes and fibroblasts, 
as well as the transdifferentiation of these last into pro-fibrotic myofibroblasts, parallels renal 
leukocyte infiltration, from the early beginning of renal disease. Furthermore, these processes 
follow the evolution of CKD, becoming autonomic and leading to excessive production of EM 
and fibrosis [9, 14, 32, 53].
Authors (first, last) and year Ref. Species CKD studied Molecules/cells studied
Gong W, Zhang A. 2016 [36] Mouse 5/6 nephrectomy (NX) NLRP3
Souza AC, Star RA. 2015 [37] Mouse 5/6 nephrectomy (NX) TLR4
D’Apolito M, Giardino I. 2015 [38] Mouse 5/6 nephrectomy (NX) Urea as a DAMP
Lehners A, Wenzel UO. 2014 [39] Mouse 5/6 nephrectomy (NX) Myeloperoxidase 
(MPO)
Correa-Costa, Camara NOS. 
2011
[40] Mouse Adenine-induced tubule interstitial 
nephritis
TLR2, TLR4, MYD88, 
ASC, CASP1
Fanelli C, Zatz R. 2011 [19] Rat CKD caused by AT1 blockade during 
nephrogenesis
T-lymphocytes
Vilaysane A, Muruve DA. 
2010
[41] Mouse Unilateral ureteral obstruction (UUO) NLRP3
Rodriguez-Iturbe, Vaziri ND. 
2004
[42] Rat Spontaneously hypertensive rats (SHR) NFKB system, T-cells
Utimura R, Zatz R. 2003 [28] Rat ST-induced DN T-lymphocytes
Fujihara CK, Zatz R. 2001 [29] Rat L-NAME-induced nitric oxide synthase 
inhibition
T-lymphocytes
Donadelli R, Zoja C. 2000 [43] Rat 5/6 nephrectomy (NX) NFKB system
Fujihara CK, Noronha IL. 
1998
[35] Rat 5/6 nephrectomy (NX) T-lymphocytes
Table 1. Evidences of innate and adaptive immunity activation in nonimmune-mediated CKD.
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Authors (first, 
last) and year








NLRP3 CP-456,773 CP-456,773 prevented 
kidney fibrosis in a 
murine model of crystal 
nephropathy induced 








NFKB system PDTC PDTC prevented p65 
nuclear translocation, 
limited formation of 
renal interstitial foreign 
body granulomas, 
reduced the expression 
of Ifng, Il6, Fsp1, Mcp1 
genes, and strongly 
attenuated interstitial 
fibrosis/inflammation
Kim JE, Cha 
DR. 2013
[46] Mouse db/db 
genetically-
induced DN




and oxidative stress, 
but also improved 
renal functional and 
structural changes 
through both metabolic 
and anti-inflammatory 
effects in the kidney
Gilbert RE, 
Kelly DJ. 2012





TGFβ FT011 FT011 attenuated 
hypertension, GS, and 
renal macrophage 
infiltration in Nx, 
as well as reduced 
albuminuria, GS, renal 
interstitial fibrosis, and 
inflammation in ST-DN





NFKB system PDTC PDTC significantly 
decreased the 
percentage of CTGF+ 
cells, the mRNA for 
TGF-β, CTGF, TGF-β, 
ICAM-1 and collagen 








TGFβ Tranilast Fibrosis and tubular 
injuries were attenuated 
in UUO rats treated with 




[50] Rat 5/6 
nephrectomy 
(NX)
NFKB system PDTC PDTC attenuated 
renal injury and 
inflammation, as well 
as the density of cells 
staining positively for 
the phospho p65 subunit
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4. The immune system and kidney disease
The immune system (IS) is composed by a set of structures, cells, and processes that together 
enable an organism to recognize their self-elements from the foreign and potentially patho-
genic ones, producing then, a physiological response consistent with the nature of the rec-
ognized element, which can be either a self-harmless protein or a dangerous bacterium [54]. 
As part of these systems, there are the so-called nonimmunological physical, chemical, and 
biological barriers and the immunological components itself, represented by innate and adap-
tive mechanisms of cellular and humoral immune response [54, 55].
In a simplistic way, the IS is responsible for four different body functions. The first one is the 
immune tolerance, the property that allows the body to recognize self-cells, proteins, and 
Authors (first, 
last) and year
Ref. Species CKD studied Target cell/molecule Drug/compound Related improvements
Utimura R, 
Zatz R. 2003
[28] Rat ST-induced 
DN
T-lymphocytes MMF MMF prevented 
albuminuria, GS, and 




[51] Human Human DN TGFβ, TNFa Pirfenidone Treatment with 
pirfenidone, which 
has been shown to 
inhibit renal fibrosis in 
experimental models, 
prolonged the period of 
conservative treatment 
of CKD in patients with 
















[52] Rat 5/6 
nephrectomy 
(NX)
T-lymphocytes MMF Segmental sclerosis, 
interstitial fibrosis, 
and renal infiltration 
by CD43+ and ED1+ 





[35] Rat 5/6 
nephrectomy 
(NX)
T-lymphocytes MMF MMF significantly 
prevented GS and 
interstitial expansion in 
NX rats
Table 2. Studies using experimental CKD development and its renoprotective effects.
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other constitutive elements, producing a response of tolerance and preventing autoimmune 
reactions. This particular state of IS unresponsiveness is also essential to ensure the regular 
fetal development during pregnancy and to allow the colonization of human skin, digestive 
tract, and vagina by beneficial microorganisms referred as microbiota [56, 57].
The second and most well-known function of IS is the immunity itself. It is the ability to 
recognize foreign proteins and molecules, which may indicate the presence of invading 
microorganisms, such as bacteria or other parasites, and respond to these foreign elements 
with both cellular and humoral defenses, protecting the organism against infection [54]. 
Additionally, through its third property, immune surveillance, the IS patrols the body to 
recognize and destroy self-cells infected by virus or even constitutive cells that become can-
cerous or suffer phenotype alterations due to genetic mutations [54, 55]. For immune sur-
veillance to work, cancer and/or mutated cells must express specific antigens that are not 
frequently found on normal cells, otherwise the IS would recognize them as “self” and be 
tolerant of them [58, 59].
Finally, the last property of IS is the ability of self-controlling the immune response. 
Through a complex mechanism of feedback and cell-to-cell communication, involving a 
number of cytokines and cell-cytokine receptors, IS modulates its response, which can be 
either tolerance or immunity, according to the specific stimulus to which the organism 
is subjected to [54]. This property is known as immunoregulation and is of paramount 
importance, not only for the kidneys but also for the whole organism. Failures on the 
immunoregulation may lead either to the development of autoimmune diseases that can 
impair renal function, such as systemic lupus erythematosus (SLE), whose renal involve-
ment is a severe type of GN called lupus nephritis or to the vulnerability to opportunistic 
infections, leading to repeated episodes of pyelonephritis and/or immune-mediated GN 
due to the accumulation of antigen-antibody complexes in the glomerular filtration barrier 
(GFB) [12].
The integrity of the epithelial tissue can be listed as one of the most important nonimmuno-
logical physical barriers against infection. The skin represents the largest organ of the human 
body and its main function is to delimit the organism, separating it and protecting it from the 
environment that surrounds it. Of course, it is not an insurmountable insulation, since this 
would be incompatible with the maintenance of life: water, atmospheric gases, and ions are 
able to cross the epithelial barrier simply due to passive processes such as osmosis and diffu-
sion or through active transmembrane transport.
However, macromolecules, such as high-weight proteins or even whole cells are not able to 
transpose the barrier formed by epithelial tissue in a normal physiological situation, making 
the area covered by the intact epithelium protected from invasive pathogens. Accordingly, 
epithelial injury and/or scarification provide the invasive parasites a chance to enter into 
their future host [54, 55]. Some virulent microorganisms can produce elements capable of 
puncturing or injuring the epithelial tissue, opening a gateway to the host organism. Certain 
strains of uropathogenic Escherichia coli (UPEC), for instance, produce proteolytic enzymes, 
cytotoxic necrotizing factors, and numerous adhesive molecules (adhesins) as part of their 
invasion arsenal [60].
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UTI is a worldwide health problem that affects over 13 million of people each year in the US. It 
is currently the most common infection in adult females and, in nearly all cases, it is caused 
by a few strains of UPEC. Although the symptoms of an uncomplicated UTI can be relatively 
mild, it can progress to pyelonephritis, leading to fever, nausea, vomiting, and, in about 30% 
of cases, bacteremia and risk of sepsis. Moreover, recurrent UTI may contribute to additional 
problems, including renal scarring, CKD, and an increased risk for developing bladder cancer 
[60]. Besides the presence of UPEC and the toxins produced by them in the urinary tract, there 
are evidence that proteinuria can itself cause injury to the renal and urinary epithelium. Since 
proteins are expected to be retained in the GFB, increased protein concentration in the urinary 
fluid is considered an irritating and pro-inflammatory factor for the tubular, ureteral, and 
bladder epithelium, leading to enhanced protein reabsorption by the tubular epithelial cells, 
overload of their catabolic capacity, leukocytes infiltration, and corruption of the integrity of 
the urinary epithelial barrier [54].
The intestinal and ureteral peristaltic movement and the flow of fluids like vomiting, diar-
rheal, or the urinary stream itself are also important physical barriers against infection, pre-
venting the onset and permanence of microorganisms in the digestive system and in the 
lower urinary tract. In addition to these physical barriers, the maintenance of low pH in 
some body fluids is one of the chemical physiological strategies of greater prominence to 
avoid infections. Accordingly, low stomach and urinary pH can destroy most of the para-
sitic organisms which, by chance, succeed in penetrating these systems [55]. The last, but 
not least, of the “nonimmunological” barriers that protect our body from infection is the 
biological barrier, represented by the normal microbiota, a complete ecosystem composed 
by harmless microorganisms that live in balance with our body. The benefits of having the 
intestines, skin, and vagina occupied by specific strains of innocuous bacteria were once 
thought to be limited to the reduction of pathological colonization, due to the competition 
among the invaders and the resident flora. Nowadays, we know that the microbiota lives in 
fact in a mutualistic symbiosis with our body, benefiting themselves and the host [54, 55, 61].
The integrity of our intestinal microbiota, for instance, is essential to the digestion of a num-
ber of food components, making the absorption of important nutrients easier. Moreover, the 
anaerobic bacilli that inhabit the vaginal cavity are responsible for the maintenance of acid 
pH in that region, since they produce lactic acid as an anaerobic respiration metabolite, keep-
ing the vagina free of fungal colonization. It is of note that the resident microbiota lives in a 
delicate balance with our IS. Its growth is controlled and limited by phagocytic cells and other 
elements of the IS, and the occurrence of imbalances in the property of immunoregulation, 
such as immunity reduction due to illness, immunosuppression, stress, or malnutrition, may 
lead to an exacerbated growth of microbiota population, which is potentially harmful for the 
human organism and should be controlled [54, 61].
5. Inflammation and innate immune response
When the above mentioned nonimmunological natural barriers are overcome by pathogens or 
other irritative elements, the immune response is initiated through the inflammatory reaction, 
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as an attempt to restore tissue integrity. In case of infection, for instance, the elimination of 
invading microorganisms becomes a necessary condition for tissue repair. Inflammatory reac-
tion depends on the action of specific blood cells called leucocytes. Under normal physiologi-
cal conditions, there are around 5000 and 10,000 leukocytes per blood microliter, but these 
numbers significantly rise in the presence of an infection. Mature leukocytes can be classified 
both according to their original lineage (myeloid or lymphoid cells) and/or to the number of 
cellular nuclei they appear to have under light microscopy (mononuclear or polymorpho-
nuclear cells), as illustrated in Figure 2 [32, 54].
Mononuclear cells represent 35% of the total peripheral blood leukocytes. This broadest cat-
egory is composed by monocytes: phagocytic cells that give rise to both macrophages and 
dendritic cells; mast cells, which are mainly responsible for vasodilation on inflammatory 
processes; lymphocytes, the effectors of our specific immune response, and finally, the natural 
killer cells (NK). The remaining 65% of blood leukocytes are represented by the polymorpho-
nuclear cells, which are didactically subdivided into three different groups, according to their 
affinity with acid (eosinophils), alkaline (basophils) or both (neutrophils) histological dyes; 
these last being the first cell type to reach an injured area of the organism and initiating the 
inflammatory response. Leukocytes whose cytoplasm is rich in granules of enzymes and cyto-
toxic substances, such as reactive oxygen species, are generally called granulocytes. Basophils, 
eosinophils, and neutrophils can be called granulocytes. Macrophages and dendritic cells also 
have a considerable amount of granules in their cytoplasm; however, they are described as 
phagocytes, due to their ability to phagocyte invading microorganisms. All leukocytes are 
capable of producing a broad range of chemical mediators involved in the immune response 
(generally called cytokines) in response to lesions or to the presence of microorganisms. In 
addition to being responsible for the synthesis of these cytokines, leukocytes are also respon-
sive to the action of these mediators, which promote, among other biological effects, leuko-
cyte chemotaxis toward the inflammatory focus as well as its activation [32, 54, 55]. Cytokines 
are soluble glycoproteins, which may have autocrine, paracrine, or endocrine action. A frac-
tion of these mediators have been at least partially described, however, there is still an almost 
infinite range of little known pro-inflammatory cellular signaling molecules, whose activity 
has not yet been fully established.
As far as we currently know, once the nonimmune body barriers are overcome by a patho-
gen or a dangerous substance, a microscopic battle begins in the injured tissue. The first 
line of defense of our immune system is the innate immunity, which comprises a group 
of cells, intracellular mechanisms, and chemical mediators, extremely conserved evolution-
arily. Long before vertebrates first appeared on Earth, their primitive ancestors already had 
effective systems of immune cells recruitment, production of cytokines, activation of the 
complement cascade, identification of foreign elements through transmembrane and intra-
cellular molecular pattern recognition receptors (MPRR), inactivation of pathogens through 
the production of reactive oxygen species (ROS), antimicrobial peptides and lytic enzymes, 
and, finally, removal of invader microorganisms through phagocytosis. Although innate 
immune system is a nonspecific evolutionarily older defense strategy, it is a fast mechanism 
that comes into play immediately or within hours of the appearance of a foreign element in 
the body, initiating the inflammatory process [32, 37–42, 54].
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Right after tissue aggression, the MPRRs of injured cells, which may be epithelial, endothelial, or 
mesangial cells, as well as resident phagocytes and fibroblasts, recognize pathogen- associated 
molecular patterns (PAMPs) that may indicate the presence of invading microorganisms 
and damage-associated molecular patterns (DAMPs), released by self-cells under cellular 
Figure 2. Leukocyte classification. Leukocytes can be classified as myeloid or lymphoid cells, according to their 
hematopoietic origin, or as mononuclear or polymorphonuclear cells, according to the number of cellular nuclei and 
cytoplasmic granules they appear to have, in their mature circulating form, under light microscopy.
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 suffering. Bacterial lipopolysaccharide (LPS), flagellin, peptidoglycans, glycolipids, zymosan, 
and profilin, as well as single-stranded DNA (ssDNA) and double-stranded RNA are exam-
ples of PAMPs. In turn, Interleukines IL-1β and IL-18, extracellular HMGB1, ATP, and DNA, 
as well as uric acid crystals can be considered DAMPs [37–42].
After this first identification, local cells synthesize and release vasoactive mediators that 
promote vasodilatation and increase the local blood supply, causing heat and flushing; 
common features of inflammation. The concomitant activation of resident innate immune 
cells also takes part in the process. Under physiological conditions, the most common 
kidney resident immune cells are tissue macrophages and dendritic cells. It is of note that 
these last acts as sentinels in homeostasis, local injury, and infection, rapidly producing 
neutrophil-recruiting chemokines. In a less extent, mast cells are also seen in renal tis-
sue and have been pointed out as local renal producers of RAAS components [14, 18]. 
Once activated, in addition to increasing the renal production of Ang II, mast cells release 
the content of their cytoplasmic granules of histamine; a biogenic amine that promotes 
increased vascular permeability by distancing endothelial cells (enlargement of endothe-
lial fenestrae) near the injured region. As a result, there is a blood plasma extravasation 
from local blood vessels to the injured region, diluting eventual toxins produced by invad-
ing microorganisms, and bringing the proteins of complement system to the inflammation 
site [54, 55]. This interstitial accumulation of plasma promotes both edema and local pain, 
due to the compression of nerve endings. The next step is the diapedesis, or transendo-
thelial migration, which is the leukocyte outflow from the bloodstream toward the focus 
of inflammation. This process is only possible due to a complex chemical communication 
system between the injured local tissue, the endothelial cells and the leukocytes itself, as 
illustrated in Figure 3.
The first cell types to reach the inflammatory focus are neutrophils, followed by circulat-
ing monocytes, which upon reaching the tissues become macrophages. Phagocytes also 
are able to reach the inflammatory spot and recognize PAMPs and DAMPs through two 
potential strategies: (1) phagocytosis followed by digestion of the microorganism and (2) 
production and excretion of anti-microbial compounds, as nitric oxide (NO), and ROS 
such as superoxide anion (O
2




). The acute phase of inflam-
mation can promote systemic effects. Activated macrophages, for example, release IL-1β 
and tumor necrosis factor (TNFα), cytokines that bind to our thermoregulatory recep-
tors causing body temperature rising (fever), and stimulate the hypothalamic-pituitary-
adrenal axis, leading to increased production of corticoid hormones, including renin, by 
the adrenal gland [54, 55]. Moreover, TNFα acts on the bone marrow, accelerating leuko-
cyte proliferation. At this initial nonspecific phase of inflammatory response, the phago-
cytic capacity of neutrophils, monocytes, and macrophages does not depend on specific 
antigenic recognition, on neither the immune memory nor the presence of antibodies. 
Resistant microorganisms, as well as remaining phagocytes, are then drained through the 
lymphatic vessels to the nearest lymph node, where the antigens will be presented to the 
lymphocytes, initiating a more complex and long-lasting reaction, the adaptive immune 
response [32, 54, 55].
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6. Innate immune response and nonimmune-mediated CKD
In the past years, renal activation of innate immune mechanisms by sterile elements has been 
demonstrated in nonimmune-mediated human nephropathies. Moreover, such activation 
of innate immunity seems to be positively correlated with the progression of renal injury in 
a variety of experimental models of CKD (Table 1). Our understanding of the mechanisms 
underlying the triggering of sterile inflammation was largely enhanced after the discov-
ery of specific MPRRs: the toll-like receptors’ (TLRs) and the NOD-like receptors’ (NLRs) 
families; primarily found in leukocytes, but also present in epithelial and endothelial cells. 
Once activated, transmembrane and cytoplasmic TLRs trigger multiple intracellular events, 
involving adaptor proteins, such as MyD88, Mal/TIRAP, and TRAM, leading to nuclear 
translocation of transcription factors such as IRF3, IRF7, and NFΚB, known to induce a 
variety of pro-inflammatory genes [32, 40]. On the other hand, NLRs are another class of 
intracellular MPRRs, very responsive to the presence of DAMPs. Their activation promotes 
the assembly of molecular complexes known as inflammasomes, such as the NOD2, NLRP1, 
NLRP3, NLRC4, etc. Inflammasomes assembly also promotes NFKB and MAPK activation, 
as well as the conversion of the inactive Pro-caspase 1 into the pro-inflammatory enzyme 
Caspase 1 (CASP1), which in turn, promotes the maturation of interleukins IL1β and IL18, 
thus amplifying the inflammatory response [36–41]. As mentioned above, the activation of 
these two main families of MPRRs, as well as, the components related to their intracellular 
signaling pathway were already described to be present in both human and experimental 
CKD. A proposed mechanism for sterile activation of immune response in nonimmune-
mediated CKD is illustrated in Figure 4.
Figure 3. Diapedesis. Inflammatory response initiates right after the recognition of a foreign element by the MPRRs of 
host cells, particularly the toll-like (TLRs) and NOD-like receptors (NLRs). Damaged cells release specific chemokines 
(CCL-2, -3, -4, -5, -11, -20 and CXCL10), which attract the circulating leukocytes, guiding their migration through a 
gradient of concentration in the bloodstream toward the inflamed area. When these cells reach the blood vessels with the 
highest concentration of chemokines, they firmly adhere to the endothelium and initiate a rolling process, getting closer 
to the inflamed region. Once near from the inflammation site, leukocytes stop rolling, change their shape by spreading 
on the endothelium, and finally pass through the enlarged endothelial fenestrae, reaching the potentially infected 
tissue. This process is called diapedesis and it is only possible due to the chemical affinity between the constitutive 
integrins, present on the surface of leukocyte cellular membrane, and some specific endothelial adhesion molecules, 
such as selectins E and P, which stimulate leukocyte rolling, vascular cell adhesion molecule 1 (VCAM-1), intercellular 
adhesion molecule 1 (ECAM-1) and platelet and endothelial cell adhesion molecule 1 (PECAM-1), which contribute to 
the attachment of leukocytes to the endothelial membrane and to their transmigration through the endothelial barrier.
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Accordingly, experimental studies have been shown that chemical blockage of inflamma-
some NLRP3, NFKB system, and IL1β, limits blood pressure rising, albuminuria, creatinine 
retention, and renal histological alterations in different murine CKD models. Moreover, Tlr2, 
Tlr4, and Nod2 knockout (KO) mice develop less tubulointerstitial nephritis and renal fibrosis 
when submitted to kidney injury [40]. The activation of innate immunity pathways in nonim-
mune-mediated CKD may represent an important link between nonspecific insults; such as 
glomerular wall stretching, due to glomerular hypertension and hypertrophy, tubular expo-
sure to high protein, glucose or uremic toxins concentration, tissue damage by the presence 
of crystals; and late events, such as GS and interstitial fibrosis. Innate immune intracellular 
mechanisms are represented in detail in Figure 5 [2, 18, 21, 54]. Since cell damage may further 
stimulate innate immunity, a positive feedback may establish, leading to the engagement of 
adaptive immunity, perpetuating inflammation, and culminating in the establishment of end-
stage renal disease (ESRD).
Figure 4. Renal sterile inflammation. Beyond to be activated by pathogens, MPRRs are also sensible to molecules 
currently related to cell damage (DAMPs). These sterile stimuli may represent the link between the initial features 
of nonimmune renal aggression and the establishment of chronic kidney inflammation. It is currently known that 
different renal cells present the intracellular machinery necessary to activate innate immune response, from endothelial 
to resident dendritic cells. TLRs and NLRs are stimulated in tubular epithelial cell exposed to DAMPs starting an 
intracellular intricate response that leads to the release of pro-inflammatory interleukins and chemokines (A). These 
intercellular signaling compounds are capable of recruiting circulating leukocytes to the renal parenchyma, as well as 
to activate resident interstitial macrophages, dendritic and mast cells, similarly to what occurs in an infection episode 
(B). Moreover pro-inflammatory interleukins released by both epithelial cells and renal immune sentinels can activate 
resident fibroblasts leading to their transdifferentiation into profibrotic myofibroblasts; cells specialized in producing 
large amounts of EM proteins and further pro-inflammatory signaling molecules. Additionally, glomerular sterile 
damage can also trigger leukocyte recruitment through the activation of innate immunity pathways. Endothelial 
cells of glomerular capillaries potentially react to mechanical stress caused by tissue stretching due to glomerular 
hypertension and hypertrophy by releasing DAMPs. This possible event promotes mesangial cells proliferation 
and EM overproduction, which may lead to glomerulosclerosis and the activation of further pro-inflammatory 
mechanisms (C).
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7. Adaptive immune response
As previously mentioned, in the presence of an infection the microorganisms, which were not 
eliminated by the innate immune response, are drained together with remaining  phagocytes 
Figure 5. Some intracellular mechanisms of sterile innate immune reaction. Many different sterile stimuli can be 
identified as DAMPs by epithelial, endothelial, mesangial cells and also by renal resident leukocytes. Once a DAMP 
is recognized by a TLR, for instance, it leads to the activation of NFΚB system, one of the most important intracellular 
pro-inflammatory pathways. The NFΚB system is composed by the subunits p50 and p65, which in physiological 
conditions are maintained in their inactive form in the cytoplasm due to binding to the inhibitory protein IKB. Under 
stimulation, IKB is degraded, releasing the p50/p65 heterodimer, which penetrates into the cell nucleus to bind to 
DNA and act as a transcription factor, promoting the synthesis of a bunch of pro-inflammatory proteins, including 
the immature interleukins pro-IL1β and pro-IL18 and the active IL-6, VCAM, PAI-1, MCP-1 and IFNγ. It is of note that 
the NFΚB system is not exclusively activated by TLRs signaling, but also by oxidative stress, Ang II and other pro-
inflammatory mediators. On the other hand, the identification of intracellular DAMPs by a NLR, such as the NLRP3 
for instance, promote the assembly of a molecular complex known as NLRP3 inflammasome, that also promotes NFΚB 
system activation, as well as the conversion of the inactive pro-caspase 1 into the pro-inflammatory Caspase 1 (CASP1), 
promoting IL1β and IL18 maturation, thus amplifying the inflammatory response.
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through the lymphatic vessels to the nearest lymph node, where a most specific and long 
lasting reaction begins: the adaptive immune response. It is important to emphasize that 
macrophages, dendritic cells, and other innate phagocytes represent the link between the 
nonspecific and the specific immune response. These leukocytes are designated as antigen 
presenting cells (APCs), since they have the ability of presenting foreign molecules to the 
lymphocytes in the lymph nodes, thereby activating and stimulating these specific cells. 
Lymphocytes are mononuclear leukocytes involved with the specific immune response. 
They originate from a lymphoid progenitor cell in the bone marrow, and may undergo dif-
ferentiation in the bone marrow itself, been called B-lymphocytes or simply B-cells, or in 
the thymus, called T-lymphocytes or T-cells [54, 55]. Once the APCs phagocyte an invading 
microorganisms, they digest their proteins (antigen processing) and migrate to the lymph 
nodes, where they expose small peptide portions of the invader in the surface of their cel-
lular membrane, associated with their molecules of the major histocompatibility complex 
of class II (MHC II). Both types of lymphocytes are able to recognize processed antigens 
associated with molecules of the MHC II of APCs through their membrane receptors (TCR 
of T-lymphocytes or BCR of B-lymphocytes). Unstimulated B or T lymphocytes, also called 
“naive” cells are generally small and present scarce cytoplasm. However, once stimulated, 
they became “effector lymphocytes,” increase in size, have the cytoplasm hypertrophied 
and suffer mitosis, promoting clonal amplification, thus increasing the number of cells that 
would be sensitive to that specific activating antigen [32, 54].
In an extremely simplified view, when an antigen is recognized by the TCR of a naive T-cell, 
this leukocyte is activated, initiating the cellular adaptive response. First of all, the effector 
t-cell give rise to two different cell types through cell division: the T-Helper lymphocyte, 
that have the CD4 glycoprotein on the surface of their cell membrane (CD4+ T-cell), and the 
Cytotoxic T lymphocyte, characterized by the presence of CD8 in its membrane (CD8+ T-cell). 
Both CD4+ and CD8+ T-cell will be sensitive to the same antigen that promoted the activa-
tion of the T-Helper cells migrate to the inflamed area and, according to the type of stimulus 
they receive, these cells differentiate into one of the five known phenotypes: Th1, Th2, Th17, 
Tfh, and Treg [55]. Most of these subtypes of T-cells produce pro-inflammatory cytokines that 
acts especially upon macrophages, attracting them close to the target antigen, giving them 
increased membrane mobility and increasing their phagocytic and microbicidal potential. 
Only the Treg phenotype is described to release anti-inflammatory mediators, thus contribut-
ing to immunotolerance.
Cytotoxic T lymphocytes, in turn, can directly lysate bacteria, virus-infected cells, as well as 
self-cells that have suffered genetic mutation. Once the cytotoxic T-lymphocyte gets in touch 
with the target microorganism or antigen, a series of granzymes, perforins, and other cytotoxic 
molecules are released from within their cytoplasmic granules directly into the extracellular 
medium. Perforins are molecules that promote the formation of pores in the plasma membrane 
of target cells, causing abrupt entry of liquid, due to osmotic pressure, into the cytoplasm of 
these cells, leading to its apoptosis. Furthermore, both T-Helper and Cytotoxic lymphocytes give 
rise to memory CD4+ and CD8+ cells, respectively. This process is illustrated in Figure 6. Unlike 
the other populations of T-lymphocytes, memory T-cells may be inactive for years in the blood-
stream, generating copies of themselves; thus, maintaining the memory of the recognition of the 
antigen that caused the activation of its precursor. Such cells are readily activated in the presence 
of a reinfection, being extremely important to defend our body from recurrent infections.
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On the other hand, when a foreign antigen is recognized by the BCR of a naive B cell, the 
humoral branch of adaptive immune response sets in motion. Activated B lymphocytes, or 
plasmocytes, synthesize specific antibodies against the invading microorganism. The anti-
bodies produced by plasma cells may remain adhered to the cellular membrane of B-cells, 
promoting the binding of the cell as a whole to the parasite antigen, or be released to the 
bloodstream. In both cases, binding of the specific antibody to the antigen of invading micro-
organism promotes opsonization of its phagocytosis by neutrophils, macrophages, mono-
cytes, and dendritic cells, besides promoting the neutralization of microbial toxins. Activated 
B-cells also produce memory B-cells, important to generate an accelerated and more robust 
antibody-mediated immune response in the case of re-infection by the same antigen [54].
8. Adaptive immune response in nonimmune-mediated CKD
Similar to the innate arm of immune response, adaptive immunity seems to be activated in both 
human and experimental CKD, even when the initial renal injury is not caused by infection or by 
any autoimmune condition. Moreover, the recruitment of lymphocytes to the renal parenchyma 
Figure 6. Presentation of antigens to lymphocytes and the onset of adaptive immune response. Mechanisms that link 
innate and adaptive immunity and the onset of the activation of lymphocytes.
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often correlates positively with worsening of renal function loss. T-lymphocytes are commonly 
seen in the kidneys of rats submitted to NX, streptozotocin-induced (ST) DN, chronic nitric oxide 
inhibition, among others. Accordingly, the treatment of these animals with mycophenolate mofetil 
(MMF), a lymphocytic inhibitor, was shown to reduce albuminuria, hypertension, glomerular, 
and interstitial damage. Although the exact mechanisms by which adaptive response is triggered 
in such “sterile” conditions are presently unclear, some hypotheses have gained strength with the 
development of experimental studies over the last decades [28, 29, 35, 52].
One of these hypotheses points to Ang II as a pivotal element to stimulate the activation of 
specific cellular immunity in nonimmune-mediated nephropathies. The role of Ang II in the 
activation of adaptive immunocompetent cells in vivo is increasingly recognized by the benefi-
cial effects of ARBs and ACE is in several models of immune-mediated diseases and even as 
an adjuvant in avoiding allograft rejection after kidney transplantation. It was widely demon-
strated that experimental venal infusion of Ang II in rodents induces T lymphocyte migration 
to specific target organs, such as the kidneys and the spleen. Moreover, these infiltrating lym-
phocytes assume mainly Th1 and Th17 pro-inflammatory phenotypes, increasing the release of 
IFN-γ and decreasing IL4 concentration in these organs, thus participating in the mechanism 
that drives to inflammation and hypertension. Accordingly, in vitro studies showed Ang II to 
act as an “antigen” upon cultured mouse spleen lymphocytes, promoting their activation and 
further clonal proliferation. T-cells have been shown to be also activated in the murine model 
of DOCA-salt hypertension, supposedly a nonimmune-mediated condition, in which Ang II 
plays an important role. In this model, pharmacological inhibition of the T-lymphocyte CD28 
receptor and of its co-stimulatory protein CD80 prevented the development of hypertension 
and consequent renal injury. Corroborating these findings, further studies showed that Cd80 
KO mice are renoprotected when submitted to the Ang II-induced hypertension model [35, 52].
Curiously, Ang II was shown to be released by activated T cells during the blood-stage of plas-
modium infection in an experimental model of malaria. Once T-cells are described to have the 
complete intracellular machinery to synthesize all RAAS components, including transmem-
brane AT1 receptors, Ang II produced by the infected cells may promote the recruitment and 
activation of further naive lymphocytes. According to this study, Ang II binding to the AT1 
receptors of cultured T-cells leads to: upregulation of CD69 and CD25, increased cellular adhe-
sion, and migration due to overexpression of CCR2 and CCR5 chemokine receptors and LFA-1 
adhesion molecule, as well as T-cell differentiation, observed by the increased production of 
IL17 and IFN-γ and by the presence of cell perforins. However, the reasons why intracellular 
RAAS seems to be overactivated in T-cells exposed to inflammation, remains unknown.
Besides Ang II, advanced glycation end products (AGEs), represent another possible sterile 
“antigen” which may activate adaptive immunity in nonimmune-mediated CKD. AGEs are 
proteins or lipids that become glycated as a result of exposure to high glucose levels. Under 
some pathologic conditions, such as DM, sustained hyperglycemia and ROS production lead 
to increased AGE formation. Excessive AGE production is involved with the development 
and worsening of many degenerative diseases; including DN. Human AGE receptor (RAGE) 
is a multiligand cell surface MPRR that also binds Hmgb1, S100, and other DAMPs. Highly 
expressed in macrophages, T-, and B lymphocytes, RAGE contributes to inflammatory 
mechanisms, including the differentiation of Th0 in Th1 cells. RAGE-mediated leukocyte 
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Figure 7. Some mechanisms of adaptive T-cell sterile activation. Through the binding of processed antigens to the 
T-lymphocyte receptors TCR, CD4, CD8 and CD28, an intracellular mechanism is set in motion, leading to the activation 
of NFKB system, with further production of immature interleukins pro-IL1β and pro-IL18 among other mediators. 
Such sterile antigens particles are believed to be originated from phagocyted DAMPs, recognized by the innate immune 
APCs, as previously described. Ang II also exerts a pivotal role in the activation of T cells. Although the mechanism that 
leads activated T cells to overproduce intracellular RAAS components remains unclear, it is well known that, in addition 
to enhance Ang II production, when subjected to inflammatory stimuli, T cells also expose more AT1 receptors, making 
themselves more responsive to Ang II produced by other leukocytes or by the cells of injured tissue. Through the binding 
of Ang II to its AT1 receptor, T-cells become more active, thus expressing a greater number of CCR2 and CCR5 chemokine 
receptors. Finally, T-lymphocytes have constitutively high expression of the advanced glycation end products receptor 
(RAGE). Once it binds to its specific ligand (AGE), or to other DAMPs, such as Hmgb1 or S100 proteins, it starts the 
conversion of Th0 lymphocyte toward the pro-inflammatory Th1 phenotype, which in turn, produces some of the most 
potent pro-inflammatory mediators that will further increase M1 macrophage population.
recruitment is particularly important in conditions associated with higher RAGE expression, 
such as DM. In these cases, when overexpressed in the surface of endothelial cells, RAGE 
directly mediate leukocyte recruitment, acting as a cell adhesive receptor. Moreover, AGE 
binding to RAGE result in overexpression of cytokines and pro-inflammatory molecules.
As illustrated in Figure 7, it is finally possible that the sterile DAMPs, which were, recog-
nized by the innate MPRR of APCs, processed as antigens and presented to naive t-cells 
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are able to trigger adaptive immune response in the same way PAMPs would be. However, 
further studies are required for the complete elucidation of the mechanisms involved in this 
process.
9. Conclusion
Sterile inflammation exerts a key pathogenic role to the development and evolution of 
CKD. Although all the mechanisms involved in the activation of immune response in 
 nonimmune-mediated kidney conditions are not yet fully elucidated, some of the main 
assumptions for this phenomenon were discussed here. Based on our review of the literature 
and on the proposed integrative schemes, we can conclude that both innate and adaptive 
arms of immunity can be activated in CKD, with no pathological stimulus needed. Moreover, 
chronic inflammation contributes to CKD worsening and progression, leading to GS and renal 
fibrosis. The use of anti-inflammatory drugs, chemical blockers of innate immunity and anti-
lymphocyte drugs have been shown to be partially effective to decelerate the chronic inflam-
matory process that accompanies nephropathy in experimental models of CKD (Table 2). 
However, to date, blockade of systemic and intrarenal RAAS by ACEis and/or ARBs remains 
the most effective treatment for delaying renal function loss.
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